Confirmation of results
21/08/2024 07:00
For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240821:nRSU1644Ba&default-theme=true
RNS Number : 1644B Tissue Regenix Group PLC 21 August 2024
Tissue Regenix Group plc
('Tissue Regenix' or 'the Group')
Confirmation of results
Investor presentation
Tissue Regenix (AIM: TRX), the regenerative medical devices company, confirms
that the Group's interim results for the six months ended 30 June will be
announced on Tuesday 10 September 2024.
Investor Briefing
Daniel Lee, Chief Executive Officer, and David Cocke, Chief Financial Officer,
will host a live online presentation relating to the interim results via the
Investor Meet Company platform at 4.30pm on Tuesday 10 September 2024. The
presentation is open to all existing and potential shareholders.
Investors can sign up to Investor Meet Company for free and register for the
presentation here:
https://www.investormeetcompany.com/tissue-regenix-group-plc/register-investor
(https://www.investormeetcompany.com/tissue-regenix-group-plc/register-investor)
Investors who already follow Tissue Regenix on the Investor Meet Company
platform will be de facto invited.
For more information:
Tissue Regenix Group plc www.tissueregenix.com (http://www.tissueregenix.com)
Daniel Lee, Chief Executive Officer via Walbrook PR
David Cocke, Chief Financial Officer
Cavendish Capital Markets Limited (Nominated Adviser and Broker)
Emily Watts/Geoff Nash/ Edward Whiley - Corporate Finance
Nigel Birks/Harriet Ward - ECM
Walbrook PR (Financial PR and IR) Tel: +44 (0)20 7933 8780
Charlotte Edgar / Alice Woodings TissueRegenix@walbrookpr.com
About Tissue Regenix (www.tissueregenix.com (http://www.tissueregenix.com) )
Tissue Regenix is a leading medical device company in regenerative medicine.
The Company's patented decellularisation technology (dCELL®) removes DNA and
other cellular material from animal and human soft tissue, leaving an
acellular tissue scaffold not rejected by the patient's body that can be used
to repair diseased or damaged body structures. Current applications address
many crucial clinical needs in sports medicine, foot and ankle injuries and
wound care.
This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
or visit
www.rns.com (http://www.rns.com/)
.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
. END NRASEUFWSELSESA